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Misfolding and abnormal aggregation of proteins in the brain are implicated in the pathogenesis of various neurodegenerative dis-
eases including Alzheimer’s, Parkinson’s, and the polyglutamine (polyQ) diseases. In the polyQ diseases, an abnormally expanded
polyQ stretch triggers misfolding and aggregation of the disease-causing proteins, eventually resulting in neurodegeneration. In
this paper, we introduce our therapeutic strategy against the polyQ diseases using polyQ binding peptide 1 (QBP1), a peptide
that we identiﬁed by phage display screening. We showed that QBP1 speciﬁcally binds to the expanded polyQ stretch and inhibits
its misfolding and aggregation, resulting in suppression of neurodegeneration in cell culture and animal models of the polyQ
diseases. We further demonstrated the potential of protein transduction domains (PTDs) for in vivo delivery of QBP1. We hope
that in the near future, chemical analogues of aggregation inhibitor peptides including QBP1 will be developed against protein
misfolding-associated neurodegenerative diseases.
1.Introduction
Neurodegenerative diseases are a group of disorders, which
are caused by progressive degeneration of neurons in various
areas of the brain speciﬁc for each disorder, resulting in
various neurological and psychiatric symptoms correspond-
ing to each aﬀected brain area. Few eﬀective therapies have
been established to date for these diseases, largely due to
the fact that the underlying cause of the neurodegeneration
long remained unknown. However, accumulating evidence
now indicates that many of these neurodegenerative diseases,
including Alzheimer’s disease (AD), Parkinson’s disease
(PD), the polyglutamine (polyQ) diseases, amyotrophic
lateral sclerosis, and the prion diseases, share a common
pathomechanism (Figure 1). Pathological and biochemical
studies have revealed that various protein inclusions accu-
mulate inside and outside of neurons in the diseased brains,
such as senile plaques composed of amyloid-β and neuroﬁb-
rillary tangles composed of tau in AD, and Lewy bodies
composed of α-synuclein in PD. Although the signiﬁcance of
these protein inclusions on disease pathology long remained
controversial, recent molecular genetics studies revealed that
the mutations responsible for the inherited forms of these
diseasesrendertheproteinstobepronetomisfoldandaggre-
gate, or lead to the overproduction of aggregation-prone
proteins. Furthermore, not only such genetic mutations, but
also multiple environmental factors are thought to trigger
the misfolding of otherwise normal proteins, and indeed the
sporadic cases of these diseases also exhibit similar protein
inclusions in the brain. It is noteworthy that the aggregates
composed of diﬀerent proteins accumulated in the diﬀerent
diseases all have a similar structure, namely, that they are
β-sheet-rich amyloid. In addition, genetic animal models2 Journal of Amino Acids
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Figure 1: Misfolding and abnormal aggregation of proteins as a common molecular pathogenesis of the protein misfolding diseases. The
genetic mutations responsible for the inherited forms of various neurodegenerative diseases render the proteins prone to misfold and
aggregate, or lead to the overproduction of aggregation-prone proteins, which accumulate as inclusions inside and outside neurons in the
diseased brains, and eventually cause neurodegeneration. These facts indicate that the misfolding and abnormal aggregation of proteins are
crucial in the pathogenesis of these diseases, which are known as the “protein misfolding diseases.”
expressing these aggregation-prone mutant proteins have
been found to develop similar protein inclusions as well as
neurodegeneration.Thesefacts,takentogether,havestrongly
suggested that the misfolding and abnormal aggregation of
proteins are crucial in the pathogenesis of these neurode-
generative diseases, which are hence collectively called the
“protein misfolding diseases” [1–3]( Figure 1).
Our group has been working towards establishing ther-
apies for these protein misfolding diseases, with a particular
focus on the polyQ diseases because of the following reasons.
Firstly, they are determined almost solely by a monogenic
mutation and are minorly inﬂuenced by environmental
factors unlike the other diseases. Furthermore, there is a
tightcorrelationbetweentheseverityofthegeneticmutation
and the disease phenotypes. These special characteristics
highlight the polyQ diseases as the most suitable model for
the protein misfolding diseases.
In this review, we will introduce our research towards
establishing a therapy for the polyQ diseases by targeting
the protein misfolding and aggregation, using polyglutamine
binding peptide 1 (QBP1), a small biologically active peptide
that we identiﬁed from combinatorial screening.
2.The Polyglutamine Diseases
Molecular genetics studies on inherited neurodegenerative
diseases in the last few decades have revealed a common
genetic mutation shared by a group of diseases, namely, an
expansion (>40) of the CAG repeat encoding a polyQ stretch
in each unrelated disease-causing gene, and hence these
diseases are called the polyQ diseases [4, 5]. Currently nine
diseases have been found to belong to this group, including
Huntington’s disease, spinocerebellar ataxia (SCA) type 1,
2, 3, 6, 7, and 17, dentatorubral pallidoluysian atrophy, and
spinobulbar muscular atrophy (SBMA) [6–17].
The polyQ diseases share many common characteristics,
although the responsible proteins share no particular func-
tional or sequence similarities except for the polyQ stretch.
Most of the diseases are inherited through an autosomal
dominant manner except for SBMA. The threshold of the
polyQ repeat size for disease manifestation is approximately
35–40, except for SCA6, and the length of the polyQ repeat
is tightly correlated with the age of onset and severity of the
disease. These facts taken together strongly indicate that the
expanded polyQ stretch itself causes these diseases via a gain
of toxic function mechanism, which is unrelated with the
normal function of the host protein. Indeed, expression of
an expanded polyQ stretch alone or even an expanded polyQ
stretch introduced into an unrelated protein has been shown
to cause neurodegeneration in various experimental animal
models [18–21].
As a common molecular pathogenesis of the polyQ
diseases,ithasbeenproposedthatproteinswithanexpanded
polyQ stretch become misfolded and form oligomers and
amyloid ﬁbrillar aggregates, and subsequently accumulate
as inclusion bodies within neurons, eventually resulting
in neurodegeneration (Figure 2)[ 22–26]. Various cellular
proteins have been shown to associate with the polyQ
aggregates/inclusion bodies, including transcription factors
[27,28],molecularchaperones[29,30],cytoskeletalproteins
[31], and proteasomal subunits [29], and such abnormal
associations are thought to play a role in the disease patho-
genesis, through dysfunction of the cellular processes involv-
ing these proteins. Accordingly, there have been therapeutic
approaches targeting each speciﬁc cellular process that is
compromised in the disease pathogenesis [23, 32]. However,
these attempts result in only limited therapeutic eﬀects,
since numerous cellular processes are aﬀected by expression
of the expanded polyQ protein [33–36]. In contrast to
these downstream events, misfolding and aggregation of theJournal of Amino Acids 3
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Figure 2: Molecular pathogenesis of the polyQ diseases and the therapeutic target of QBP1. Proteins with an expanded polyQ stretch are
prone to misfold into a β-sheet dominant structure, leading to their assembly into oligomers and amyloid ﬁbrillar aggregates, followed by
their accumulation as inclusion bodies within neurons, eventually resulting in neurodegeneration. The peptide QBP1 inhibits the initial
misfolding into a β-sheet dominant structure of the protein by binding to the expanded polyQ stretch, resulting in suppression of polyQ
proteinaggregationandpolyQ-inducedneurodegeneration.Questionmarksindicatestructuresforwhichcytotoxicityremainscontroversial.
expanded polyQ proteins are the most initial events of the
pathogenic cascade, and therefore ideal targets since their
intervention is expected to lead to the suppression of a broad
range of downstream pathogenic events [22, 24, 37, 38].
We therefore aimed towards establishing a therapy targeting
misfolding and aggregation of the expanded polyQ protein.
3. Identiﬁcation of the Aggregation
Inhibitor PeptideQBP1
We hypothesized that molecules capable of binding speciﬁ-
cally to the expanded polyQ stretch would interfere with its
misfoldingandaggregation.Identiﬁcationofthemonoclonal
antibody 1C2 that selectively binds to the expanded polyQ
stretch, probably by recognizing its unique structure [39],
prompted us to search for amino acid sequences (domains)
or peptides possessing similar properties, which would be
more suitable as a drug due to their smaller size and more
eﬃcient in vivo delivery. We decided to employ phage display
screening to identify peptides that bind selectively to the
expanded polyQ stretch (Figure 3)[ 40]. Eleven-amino acid
combinatorial peptide libraries expressed on the surface of
M13 phage were ﬁrst screened for their binding to a polyQ62
stretch fused to glutathione S-transferase (GST-Q62) by
enzyme immunosorbent assay. Phage clones isolated from
this ﬁrst screening were further screened for their selective
binding to pathologic length GST-Q62 compared to normal-
length GST-Q19. We ﬁnally identiﬁed six phage clones with
greaterbindingtoGST-Q62,andnamedtheencodedpeptide
sequences polyglutamine binding peptide 1-6 (QBP1-6)
(Table 1). Interestingly, most of the peptides were rich in
Trp residues, implying that hydrophobic interactions play
a role in their binding to the expanded polyQ stretch.
Table 1: Polyglutamine binding peptides isolated from phage
display screening.
Name Q62/Q19
binding ratio Sequence (X5-ﬁxed-X5)
QBP1 1.66 Ser-Asn-Trp-Lys-Trp-Trp-Pro-
Gly-Ile-Phe-Asp
QBP2 1.31 His-Trp-Trp-Arg-Ser-Trp-Tyr-
Ser-Asp-Ser-Val
QBP3 1.30 His-Glu-Trp-His-Trp-Trp-His-
Gln-Glu-Ala-Ala
QBP4 1.27 Trp-Gly-Leu-Glu-His-Phe-Ala-
Gly-Asn-Lys-Arg
QBP5 1.25 Trp-Trp-Arg-Trp-Asn-Trp-Ala-
Thr-Pro-Val-Asp
QBP6 1.23 Trp-His-Asn-Tyr-Phe-His-Trp-
Trp-Gln-Asp-Thr
SCR Trp-Pro-Ile-Trp-Ser-Lys-Gly-
Asn-Asp-Trp-Phe
We chose QBP1(Ser-Asn-Trp-Lys-Trp-Trp-Pro-Gly-Ile-Phe-
Asp), which showed the greatest diﬀerential binding aﬃnity
to pathologic length polyQ compared with normal length
polyQ for further analysis.
We ﬁrst tested our hypothesis that QBP1, a peptide
that selectively binds to the expanded polyQ stretch would
interfere with polyQ aggregation in vitro [40]. We designed
thioredoxin-polyQ (thio-polyQ) fusion proteins, and found
thatthio-polyQwithanexpandedpolyQstretch(>40)forms
aggregates in vitro in a time-, concentration-, and polyQ
length-dependent manner, which faithfully mimic the in
vivo characteristics of disease-causing polyQ proteins. We4 Journal of Amino Acids
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Figure 3: Phage display screening strategy for the identiﬁcation of peptides that selectively bind to the expanded polyQ stretch. Phage
libraries expressing random 11-amino acid sequences were ﬁrst screened for their binding to GST-Q62 via 4 rounds of binding, elution,
and ampliﬁcation. Phage clones isolated from the ﬁrst screening (350 clones) were further screened for their selective binding to pathologic
length GST-Q62 compared to normal-length GST-Q19.
coincubatedQBP1withthio-Q62,andfoundthatQBP1dra-
matically inhibits thio-Q62 aggregation in a concentration-
dependent manner, showing an almost complete inhibition
at a stoichiometry of 3:1 (thio-Q62:QBP1). A scrambled
sequence of QBP1 (SCR; Trp-Pro-Ile-Trp-Ser-Lys-Gly-Asn-
Asp-Trp-Phe) had no eﬀect on thio-Q62 aggregation. Fur-
thermore, addition of QBP1 after thio-Q62 aggregation has
started resulted in inhibition of further aggregate formation,
but it could not solubilize the aggregates already formed,
suggesting that QBP1 inhibits the earlier stages in the
aggregation process of the expanded polyQ protein [41].
4. Mechanismof Action of QBP1
To elucidate the molecular mechanisms by which QBP1
prevents aggregation of the expanded polyQ protein, we
have characterized in detail the binding of QBP1 to the
expanded polyQ stretch, and analyzed the eﬀect of QBP1 on
the conformation of the expanded polyQ protein. To charac-
terize the binding speciﬁcities and aﬃnities of QBP1 to the
polyQ stretch, we employed the surface plasmon resonance
(SPR) technique, which is a highly sensitive method for
quantitatively measuring biomolecular interactions [42]. We
found that QBP1 binds selectively to the thio-Q62 protein,
with an equilibrium dissociation constant (Kd)o f5 . 7 μM,
while it shows signiﬁcant binding to neither thio-Q0 nor
thio-Q19. These results clearly indicate the striking property
of QBP1 to speciﬁcally recognize and bind to the expanded
polyQ stretch, but not the normal length polyQ stretch. We
also investigated the relationship between the polyQ binding
aﬃnities of QBP1 and its variants and their inhibitory eﬀects
on polyQ aggregation. We found a tight correlation between
the binding aﬃnities to the expanded polyQ stretch and
inhibitory activities on polyQ aggregation of these peptides.
Among these, (QBP1)2, a tandem repeat of QBP1 exhibited
the greatest binding aﬃnity to thio-Q62 with a Kd value of
0.6μM. We therefore conclude that binding aﬃnity to the
polyQ stretch is a critical determinant of the aggregation
inhibitory activity.
Next, we analyzed the eﬀect of QBP1 on the confor-
mation of the expanded thio-polyQ protein [43]. Circular
dichroism (CD) analyses revealed that QBP1 inhibits the
conformational transition of the thio-Q62 protein to a β-
sheet dominant structure. We further demonstrated for the
ﬁrst time that this β-sheet conformational transition of
the expanded polyQ protein, which occurs at the level of
the monomer before aggregation, causes cytotoxicity. Taken
together, we conclude that QBP1 speciﬁcally binds to the
expanded polyQ protein monomer and inhibits the toxic β-
sheet conformational transition, and as a result, also inhibits
the downstream aggregation and inclusion body formation
(Figure 2).
5. The Therapeutic Effects of QBP1 Expression
inCellCultureModelsofthePolyQDiseases
We also determined whether QBP1 could exert therapeutic
eﬀects in cell culture models of the polyQ diseases [40].
Expanded polyQ proteins expressed in cultured cells have
been shown to form inclusion bodies and cause cytotoxicity
inatime-andpolyQlength-dependentmanner[44].Weﬁrst
coexpressed QBP1 fused to cyan ﬂuorescent protein (QBP1-
CFP),withvarious-lengthpolyQproteinsfusedtoyellowﬂu-
orescent protein (polyQ-YFP) in COS-7 cells, and examinedJournal of Amino Acids 5
the eﬀect of QBP1 on polyQ inclusion body formation and
cytotoxicity. We found a prominent colocalization of QBP1-
CFP with polyQ-YFP inclusions, indicating that QBP1 is
capable of recognizing the polyQ stretches in cells. Notably,
coexpression of QBP1-CFP signiﬁcantly suppressed polyQ-
YFP inclusion body formation, as well as cytotoxicity, and
the inhibitory eﬀects were stronger for shorter-length polyQ
stretches (Q45 > Q57 > Q81). Furthermore, (QBP1)2-
CFP, which has a much higher aﬃnity to the expanded
polyQ stretch, exerted an even stronger inhibitory eﬀect on
polyQ inclusion body formation, consistent with our in vitro
aggregation assay results [42].
The expanded polyQ protein is recently believed to
form soluble oligomers before microscopically visible insol-
uble aggregates and inclusion bodies in cells, and these
oligomers rather than aggregates or inclusion bodies have
been suggested to cause cytotoxicity [24]( Figure 2). We
therefore analyzed the eﬀect of QBP1 on polyQ oligomer
formation, by using ﬂuorescence correlation spectroscopy
(FCS), which is a highly sensitive technique for investigating
the dynamics of ﬂuorescent molecules at single molecule
sensitivity [45]. We found that the time-dependent decrease
in mobility and increase in size of the expanded polyQ-green
ﬂuorescent protein (polyQ-GFP) expressed in COS-7 cells,
which indicates the formation of slowly moving oligomers,
wassigniﬁcantlysuppressedbythecoexpressionof (QBP1)2-
CFP [46]. Fluorescence resonance energy transfer (FRET)
analyses also conﬁrmed that (QBP1)2 inhibits expanded
polyQ oligomer formation in cultured cells [47]. These
resultsareconsistentwithourinvitroobservationthatQBP1
inhibits the conformational transition of the polyQ protein
monomer, which occurs before oligomer and aggregate
formation.
6. Therapeutic Effects of QBP1 Expressionin
AnimalModels of the PolyQDiseases
From a therapeutic viewpoint, it is indispensable to demon-
strate the therapeutic eﬀect of QBP1 in in vivo disease
models. We employed Drosophila models to elucidate the
therapeutic eﬀects of QBP1 expression on polyQ-induced
neurodegeneration, since Drosophila models of the polyQ
diseases are well established, easy to handle, and suitable
for genetic analyses [48]. Transgenic ﬂies expressing an
expanded polyQ protein under an eye-speciﬁc promoter
demonstrate accumulation of polyQ inclusion bodies and
degeneration of the eyes. We crossed polyQ expressing
ﬂies and (QBP1)2-CFP expressing ﬂies, and found that
coexpression of (QBP1)2-CFP signiﬁcantly suppresses eye
degeneration, as well as inclusion body formation. We
next examined the eﬀect of (QBP1)2-CFP coexpression
on ﬂies expressing the expanded polyQ protein under a
panneuronalpromoter,whichcausesprematuredeathdueto
neurodegeneration. Notably, the median life span of polyQ
expressing ﬂies was dramatically improved from 5.5 days
to 52 days by coexpression of (QBP1)2-CFP, indicating that
QBP1successfullyrescuesprematuredeathofthepolyQﬂies.
Table 2: Examples of protein transduction domains.
Name Origin/design Sequence
TAT HIV-1
transactivator
Tyr-Gly-Arg-Lys-Lys-Arg-
Arg-Gln-Arg-Arg-Arg
Antp Drosophila
Antennapedia
Arg-Gln-Ile-Lys-Ile-Trp-
Phe-Gln-Asn-Arg-Arg-Met-
Lys-Trp-Lys-Lys
VP22 HSV-1 structural
protein
Asp-Ala-Ala-Thr-Ala-Thr-
Arg-Gly-Arg-Ser-Ala-Ala-
Ser-Arg-Pro-Thr-Glu-Arg-
Pro-Arg-Ala-Pro-Ala-Arg-
Ser-Ala-Ser-Arg-Pro-Arg-
Arg-Pro-Val-Asp
Polyarginine Synthetic (Arg)n
Transportan
Neuropeptide
galanin + wasp
peptide
mastoparan
Gly-Trp-Thr-Leu-Asn-Ser-
Ala-Gly-Tyr-Leu-Leu-Gly-
Lys-Ile-Asn-Leu-Lys-Ala-
Leu-Ala-Ala-Leu-Ala-Lys-
Lys-Ile-Leu
These results clearly demonstrate the eﬀectiveness of QBP1
on polyQ-induced neurodegeneration in vivo.
7. Therapeutic Effects of Protein Transduction
Domain-MediatedDeliveryof QBP1
To establish a therapy using QBP1, QBP1 needs to be
delivered into aﬀected neurons in the brain, rather than
expressed by the crossing of genetically engineered animals.
However, as QBP1 is an 11-amino acid peptide, it is too
large to cross the cell membrane eﬃciently and enter cells
on its own. To enable the eﬃcient intracellular delivery of
QBP1, we utilized protein transduction domains (PTDs),
which are peptide sequences capable of penetrating the cell
membrane and entering cells. These include the human
immunodeﬁciency virus-1 TAT, Drosophila Antennapedia
(Antp), herpes simplex virus-1 VP22, and the polyarginines
(Table 2). PTDs have indeed been shown to eﬃciently
delivervariousbiologicallyactivemoleculessuchaspeptides,
proteins, and nucleic acids into cells [49, 50].
We synthesized QBP1 peptides fused to the TAT or Antp
PTD, and conﬁrmed that both of them are eﬃciently trans-
duced into cells upon addition to the medium of cultured
cells, and inhibit inclusion body formation and cytotoxicity
of the expanded polyQ protein [51]. To determine whether
PTD-QBP1 administration is able to exert therapeutic eﬀects
on an in vivo model of the polyQ diseases, we ﬁrst admin-
istered Antp-QBP1 to a Drosophila polyQ disease model, by
addingthepeptideintotheculturefood.Oraladministration
of Antp-QBP1 remarkably delayed premature death of the
polyQ expressing ﬂies compared with the control peptide
Antp-SCR. In addition, ﬂies administered with Antp-QBP1
had signiﬁcantly fewer inclusion bodies compared to the
control ﬂies. These results indicated the potential of PTD-
mediated delivery of QBP1 as a useful strategy to establish a
molecular therapy using QBP1.6 Journal of Amino Acids
We next analyzed the therapeutic eﬀect of Antp-QBP1
administration ona mousemodel ofthepolyQ diseases[52].
Intraperitoneal injection of Antp-QBP1 resulted in a slight
improvement of the weight loss in these mice, but did not
improve the other phenotypes such as motor dysfunction
and premature death. Furthermore, we could not detect a
signiﬁcant suppression of polyQ inclusion body formation
by Antp-QBP1 administration in these mice. Although we
conﬁrmedthelimiteddeliveryofAntp-QBP1intothemouse
brain via intracerebroventricular and intrastriatal injection,
we failed to detect a signiﬁcant amount of Antp-QBP1
delivered in the brain via intraperitoneal injection. These
results imply that Antp-QBP1 is unable to eﬃciently cross
the blood-brain barrier (BBB) in mice, which is tighter than
in ﬂies.
8. Towards DesigningChemical
Analoguesof QBP1
Towards developing QBP1 as a therapeutic molecule for the
polyQ diseases, we are taking another approach, which is
designing low molecular weight chemical analogues of QBP1
with eﬃcient BBB permeability. To design low molecular
weight analogues of QBP1, we ﬁrst determined the essential
amino acids required for its activity and pharmacophores of
QBP1.
WeﬁrstsynthesizedvarioustruncationmutantsofQBP1,
and tested their activities on polyQ aggregation. We found
that truncation of Ser1 and Asn2, or truncation of Asp11
does not aﬀect the inhibitory activity on polyQ aggregation
whereas truncation of the N-terminal 4 amino acids (Ser1,
Asn2, Trp3, and Lys4), or the C-terminal 2 amino acids
(Phe10 and Asp11) results in dramatic loss of activity. These
resultsimplythatthearomaticaminoacids(Trp3andPhe10)
are required for the activity of QBP1, and we therefore
concluded that the central 8 amino acids (Trp-Lys-Trp-Trp-
Pro-Gly-Ile-Phe) comprise the minimal active sequence of
QBP1 [41]. Since other QBPs that we identiﬁed from the
combinatorial screening also share Trp/Phe-rich sequences
(Table 1), we next investigated the role of the Trp-Lys-Trp-
Trp motif of QBP1 for its activity. Although the Trp-Lys-
Trp-Trp motif alone is insuﬃcient for inhibiting polyQ
aggregation, a tandem repeat of Trp-Lys-Trp-Trp connected
by an amino acid spacer was found to be as potent as the
original QBP1, suggesting that the Trp-Lys-Trp-Trp motif
plays an important role in recognizing the polyQ stretch.
We subsequently performed more comprehensive anal-
yses on all amino acids within the QBP1 sequence by Ala
scanning and D-amino acid scanning [53]. Substitutions of
Ser1, Asn2, Lys4, Pro7, Gly8, or Asp11 to Ala did not show
any signiﬁcant eﬀects on the activity of QBP1. On the other
hand,AlasubstitutionsofTrp3,Trp5,Trp6,Ile9,orPhe10led
toa dramaticdecreasein their activityonpolyQ aggregation,
indicating that the functional groups of these hydrophobic
amino acids are essential for their inhibitory activity. Hence,
the hydrophobic property of QBP1 may be important for
its interaction with the expanded polyQ stretch. In addition,
D-amino acid substitutions revealed that the internal amino
acids (Trp3-Ile9) of QBP1 are sensitive to chirality inversion,
which probably disrupts the active conformation of QBP1.
Another study using a series of peptide analogues of
QBP1 elucidated the role of the Trp residues in the activity
of QBP1 [54]. Although N-methylation at the main chain
of Trp5 and Trp6, which would lose their potential as main
chain hydrogen bond donors, resulted in a substantial loss
of activity of QBP1, methylation of the indole nitrogen of
these residues did not aﬀect its activity, suggesting that the
hydrogen bonding potential of the indole side chains are not
necessary for the activity of QBP1.
In order to design chemical analogues of QBP1, it is also
indispensable to obtain structural information on the mode
of binding of QBP1 to the polyQ stretch. However, due to
the high insolubility of the expanded polyQ protein, it has
been a challenge to experimentally elucidate the structure of
the polyQ stretch at atomic resolution in aqueous solution.
Although a molecular dynamics study suggested hydrogen
bonding between the amide groups of Ser1 to Gly8 of QBP1
andthemainchaincarbonylgroupsofthepolyQstretch,and
the role of the steric hindrance produced by Pro7 to prevent
polyQ aggregation [55], there are some inconsistencies with
the experimental results described above. Thus, further
eﬀorts to elucidate the detailed structure of the QBP1-polyQ
complex would provide valuable information for designing
chemical QBP1 analogues as a therapeutic molecule for the
polyQ diseases.
9. Other Applicationsof QBP1
Since QBP1 is the only molecule which can distinguish
between the expanded and normal length polyQ stretch, it
is also useful for speciﬁc recognition of the expanded polyQ
stretch. Indeed, we have conﬁrmed the colocalization of
QBP1 with polyQ inclusions [40], and recently, Raspe et al.
also utilized QBP1-CFP to label expanded polyQ peptides
within inclusion bodies in cultured cells [56]. These studies
raise the possibility that QBP1 could also be developed as an
in vivo imaging probe for detection of polyQ depositions in
the brain.
Bauer et al. also employed QBP1 to recognize expanded
polyQ proteins for their speciﬁc degradation by chaperone-
mediated autophagy (CMA), in which Hsc70 recognizes
and delivers substrate proteins to the lysosome for their
degradation [57]. Coexpression of a modiﬁed QBP1, which
was fused with Hsc70-binding motifs, with expanded polyQ
proteins accelerated polyQ protein degradation, resulting in
suppression of cytotoxicity in cultured cells. They further
demonstrated that viral vector-mediated gene therapy of
the modiﬁed QBP1 decreased polyQ protein aggregation
and ameliorated phenotypes such as motor dysfunction
and premature death in polyQ disease mice while viral
expression of the original QBP1 alone also exhibited a
modest therapeutic eﬀect. These results clearly indicate the
usefulness of QBP1 as a tool for speciﬁc recognition of the
expanded polyQ protein.Journal of Amino Acids 7
10. Other Peptides/Proteinsthat Bind to
PolyQ andInhibit Aggregation
Discovery of QBP1 has facilitated research towards applying
various polyQ-binding molecules such as peptides and
proteins to prevent misfolding and aggregation of the
expanded polyQ protein like as QBP1. Kazantsev et al.
designed a bivalent peptide comprised of two normal-length
polyQ stretches connected by a spacer, which is expected
to bind to the expanded polyQ stretch, and showed that
expression of this peptide suppresses polyQ inclusion body
formation and cytotoxicity in cell culture and Drosophila
polyQ disease models [58]. We also designed a normal-
length polyQ stretch with a Pro insertion, which disrupts the
ordered structure of the polyQ stretch, and showed that this
peptide successfully delays polyQ aggregation in vitro [59].
However, since these rationally designed peptides contain
short polyQ stretches that can be recruited to expanded
polyQ aggregates, they have the risk of accelerating polyQ
aggregationandenhancingtoxicityundercertainconditions.
Furthermore, the therapeutic eﬀects of these peptides were
much weaker compared to QBP1, which is the optimal
peptide sequence identiﬁed by a combinatorial screening
approach for its speciﬁc binding aﬃnity to the expanded
polyQ stretch, and is the only molecule that has been shown
to inhibit the toxic β-sheet conformational transition of the
expanded polyQ protein [43].
Several intracellular antibodies, known as intrabodies,
which bind to the expanded polyQ protein and inhibit
its aggregation have also been identiﬁed to date. In 2001,
Lecerf et al. identiﬁed the intrabody C4 that binds to the
N-terminus of huntingtin (htt), the disease-causing protein
of Huntington’s disease (HD), by phage display library
screening [60]. Subsequently, they and other groups further
showed that expression of C4 as well as other intrabodies,
namely, MW7, VL12.3, Happ1, and EM48, all of which bind
to the polyQ adjacent regions in htt, leads to suppression
of htt aggregation and neurodegeneration in cell culture,
Drosophila,a n dm o u s em o d e l so fH D[ 60–67]. The use of
intrabodies is an attractive therapeutic approach with regard
to their high binding aﬃnity to the disease-causing proteins.
However, since the intrabodies identiﬁed so far recognize a
region in htt other than the polyQ stretch itself, they cannot
be applied for the other polyQ diseases, and may cause
unfavorable side eﬀects by binding to the wild type htt with
a normal polyQ stretch.
11.Perspectives
Inthisreview,weintroducedourtherapeuticstrategyagainst
the polyQ neurodegenerative diseases using QBP1, a peptide
sequence that speciﬁcally recognizes the expanded polyQ
stretch, which we identiﬁed from phage display screening.
Although we have provided convincing evidence on the
potential of QBP1 as a therapy for the polyQ diseases, by
demonstrating its ability to inhibit misfolding and aggrega-
tion,resultinginsuppressionofpolyQ-inducedneurodegen-
eration in vivo, the major problem we are currently facing
is its delivery into the brain. Although viral vector-mediated
gene therapy may have potential for the delivery of QBP1
into the brain, the diﬃculty in controlling gene expression,
toxicity, and limited delivery within the brain discourage this
approach. The success of PTD-mediated delivery of QBP1
and its therapeutic eﬀects in a Drosophila model of the
polyQ diseases have shed light on the potential of PTDs
for in vivo delivery of QBP1. Recently, an unconventional
secretion signal overlapped with the Antp sequence was
identiﬁed, which enables secretion from cells in addition
to entry into cells via Antp [68], suggesting the potential
of identifying or designing novel PTDs with high BBB
permeability. Since most therapeutic molecules currently
in clinical use are chemical compounds, we believe the
most promising approach is to design low molecular weight
chemical QBP1 analogues with eﬃcient BBB permeability.
Further clariﬁcation of the mode of binding of QBP1 to
the expanded polyQ stretch and detailed structural analyses
of the QBP1-polyQ complex will facilitate the designing
of chemical analogues of QBP1 as a potential therapeutic
molecule for the polyQ diseases.
Although our work has been focused on the polyQ dis-
eases, our approach could also be applied for a broad range
of other neurodegenerative diseases including Alzheimer’s
disease and Parkinson’s disease, which are caused by a
common mechanism based on protein misfolding and
aggregation. Indeed, various peptides/proteins that inhibit
protein aggregation have been reported to exert therapeutic
eﬀects in cell culture and animal models of these diseases
[69, 70]. We hope that in the near future, aggregation
inhibitor peptide-based drugs against protein misfolding
neurodegenerative diseases will be developed and bring a
cure to patients suﬀering from these currently intractable
neurodegenerative diseases.
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